Over the past 20 years, the fight against cancer has been prosecuted with increasing zeal by protein kinase inhibitors. More numerous, more sophisticated, and better targeted than ever, these anticancer weapons roll off biopharma production lines only after they succeed in kinase assays. The ultimate mission? Defeat cancer by disturbing aberrant signaling or restoring normal […]
The post Kinase Assays Sharpen Their Focus, Broaden Their Scope appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Kinase Assays Sharpen Their Focus, Broaden Their Scope